CANC

Tema Oncology ETF

$37.26 -2.18%

Recent alerts on CANC

All signals →

Scanner Unusual volume (7.8x average)

News Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025

Get push alerts for CANC

Add it to your watchlist in the app and receive every signal the moment it fires.

Download for iOS

Download for iOS